Drug intelligence / Profile preview

ENV-0205

Development stage: Preclinical
Lead developer: Envisagenics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

ENV-0205 is an investigational **RNA splicing modulator** being developed by Envisagenics for oncology, with public disclosures specifically indicating preclinical development for **triple-negative breast cancer**. Available public information is sparse, but the program appears to have emerged from Envisagenics' AI-enabled SpliceCore platform, which is used to identify disease-relevant aberrant splice variants and nominate therapeutic targets. The precise molecular identity, direct biological target, chemical composition, and route or dosage form of ENV-0205 have not been clearly disclosed in accessible public sources.

Targets

Neural precursor cell expressed developmentally down-regulated 4-like pre-mRNA exon 13 splice region

Beyond the preview

Go deeper on ENV-0205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENV-0205.

Explore the full profile